Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 29 for “"Prasugrel"”.
-
Desenvolvimento e validação de métodos analíticos para determinação de prasugrel em comprimidos revestidos
… e clopidogrel a mais comum. O cloridrato de prasugrel, um fármaco tienopiridínico de terceira geração, foi aprovado em 2009 pelo Food and Drugs Administration (FDA) e pelo European Medicine Agency (EMEA) e liberado para uso clínico com o nome comercial de Effient® como alternativa para …
-
EFFECT OF PRASUGREL IN PATIENTS WITH ASTHMA: RESULTS OF PRINA, A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED,CROSS-OVER STUDY
… we tested the effects of the P2Y12 antagonist prasugrel on bronchial hyper-reactivity of asthmatic patients. Patients/Methods: Twenty-six asthmatic patients were randomly and blindly allocated to prasugrel (10mg o.d.) or placebo for 15 days. After ≥15-day wash-out, patients were crossed-over to …
-
Αντιμετώπιση της πρώιμης (2 ώρες μετά από φόρτιση με 600mg κλοπιδογρέλη) ανεπαρκούς αναστολής των αιμοπεταλίων σε ασθενείς με οξύ έμφραγμα του μυοκαρδίου με ανάσπαση του ST διαστήματος (STEMI)
… platelet reactivity (HTPR) is present, prasugrel reloading and subsequent maintenance dose (MD), might offer faster and stronger platelet inhibition than high clopidogrel MD. Methods: In 93 STEMI patients treated by primary percutaneous coronary intervention we assessed PR using the …
-
Did prasugrel and ticagrelor offer the same benefits in patients with acute coronary syndromes after percutaneous coronary interventions compared to clopidogrel? /
… PY212 receptor inhibitor, either clopidogrel, prasugrel or ticagrelor. Despite numerous researches comparing the effectiveness and safety of these three drugs, their relative merits with regards to each other remain to be further elucidated. Objective: the aim of this research is to compare …
-
Σύγκριση τικαγκρελόρης με πρασουγρέλη σε οξέα στεφανιαία σύνδρομα: ο ρόλος τους μετά από αγγειοπλαστική και αντίσταση στην κλοπιδογρέλη
… the antiplatelet action of ticagrelor with prasugrel in acute coronary syndrome (ACS) patients with high on-treatment platelet reactivity (HTPR) while on clopidogrel after percutaneous coronary intervention (PCI). Background: Newer P2Y12 inhibitors like prasugrel and ticagrelor provide …
-
Επίδραση της αντιαιμοπεταλιακής αγωγής στη στεφανιαία ροή ασθενών μετά από οξύ στεφανιαίο σύνδρομο
Background— Prasugrel and ticagrelor provide a superior anti-ischemic action than clopidogrel, with some of ticagrelor’s benefits possibly attributed to adenosine-mediated mechanisms. We aimed to compare the effect of maintenance dose of ticagrelor versus prasugrel on coronary blood flow velocity …
-
Πρωτόκολλο μελέτης προσδιορισμού της αντιδραστικότητας των αιμοπεταλίων με τη συσκευή μέτρησης VerifyNow σε ασθενείς υπό αιμοκάθαρση: σύγκριση της διπλής δόσης κλοπιδογρέλης (150mg) έναντι πρασουγρέλης (10mg)
… was to determine the antiplatelet effects of prasugrel (10 mg/day) versus high-dose clopidogrel (150 mg/day) in HD patients who present HTPR (“High on-Treatment Platelet Reactivity”) under standard dose of clopidogrel (75 mg/day).Methods We performed a prospective, single-center, …
-
Novel P2Y12 Receptor Antagonists - Prasugrel and Ticagrelor. Systematic Review, Indirect Comparison to Clopidogrel in Cardiovascular Disease, Design of a Randomized Controlled Trial
… of the new P2Y12 receptor antagonists prasugrel and ticagrelor will increase treatment options. An overview of systematic reviews was performed to summarize available evidence on clopidogrel. Current data on prasugrel and ticagrelor were identified by a systematic review and used for an …
-
Σύγκριση της πρασουγρέλης σε σχέση με την διπλή δόση κλοπιδογρέλης σε ασθενείς που έχουν υποβληθεί σε αγγειοπλαστική και παρουσιάζουν αντίσταση στη συνήθη δόση κλοπιδογρέλης, όπως αυτή προσδιορίζεται με την χρήση του μετρητή VerifyNow
… was to determine the antiplatelet effects of prasugrel versus high-dose clopidogrel in patients with high on-treatment platelet reactivity (HTPR) after percutaneous coronary intervention (PCI) and, secondarily, their relation to cytochrome (CYP) 2C19*2 carriage.BACKGROUND:High on-treatment …
-
Antithrombozytäre Therapie beim akuten Herzinfarkt in der Notaufnahme und Blutungsrisiko im stationären Verlauf
… neuer Thrombozytenaggregationshemmer (Ticagrelor/Prasugrel) in der Notaufnahme bei Patienten mit akutem Myokardinfarkt mit einem erhöhten Blutungsrisiko verbunden ist. Methoden: Insgesamt wurden in unserer retrospektiven Studie alle 809 Patienten, die sich mit der Diagnose STEMI bzw. NSTEMI …
-
The comparative effectiveness, safety, value, and adherence of newer P2Y12 inhibitors versus clopidogrel in the context of heterogeneity
… were addressed with two newer oral agents, prasugrel and ticagrelor, which were approved in 2009 and 2011, respectively. This study aims to examine the heterogeneity in treatment effects of these antiplatelet agents and assess how healthcare providers and patients change their behaviors as a …
-
Comparative Effectiveness And Safety Of P2Y12 Inhibitors In The Secondary Prophylaxis Of Acute Coronary Syndrome
… by the US Food and Drug Administration in 2009 (prasugrel) and 2011 (ticagrelor). Compared with clopidogrel these newer agents have more potent and predictable antiplatelet aggregation profiles, attributed to consistent pharmacokinetics and dynamics. However, the evidence related to their safety …
-
Molekulare MRT-Bildgebung arterieller Thromben unter dualer Plättchenhemmung im in vivo-Mausmodell
… werden können.<br>Die Therapie mit ASS und Prasugrel führte im murinen Tierversuch zu einer ausgeprägten Hemmung der Thrombozytenfunktion in vitro, bewirkte eine signifikante Verlängerung der Blutungszeit in vivo und verhinderte das Auftreten thrombotischer Verschlüsse im …
-
Nuevo modelo de doble antiagregación y anticoagulación en infarto agudo de miocardio sometido a intervencionismo coronario percutáneo primario
… mayor potencia de inhibición plaquetaria. Prasugrel es un inhibidor irreversible del receptor P2Y12 que ha demostrado mejores resultados clínicos que clopidogrel. La hipótesis conceptual de este estudio es que en los pacientes con IAMEST, la angioplastia con stent de la arteria responsable …
-
DOES THE INHIBITION OF P2Y12 INHIBIT THE PRODUCTION OF THROMBOXANE A2 BY PLATELETS?
… vitro, and in 20 patients treated with 10 mg/d prasugrel (P2Y12 antagonist) or placebo for 14 days in a randomized, double-blind, cross-over study. TxB2 levels were also measured after stimulation of citrate-PRP by collagen (0,5μg/mL) or arachidonic acid (1mM) in an aggregometer in …
-
Determinants of clinical outcomes following primary percutaneous coronary intervention: the West Yorkshire Primary Percutaneous Coronary Intervention Outcome Study
… multivariable analysis, both ticagrelor and prasugrel were associated with lower recurrent MI compared to clopidogrel. However, only prasugrel was associated with reduced mortality, both in comparison with clopidogrel and ticagrelor. There was no difference in bleeding between the three …
-
The clinical efficacy of oral P2Y12 inhibitor antiplatelet therapies during an acute myocardial infarction in patients undergoing percutaneous coronary intervention
… to which oral P2Y12 inhibitors (clopidogrel/prasugrel/ticagrelor) exert their antiplatelet effect during the acute phase of a STEMI compared to non-ST elevation myocardial infarction (NSTEMI). Methods: The degree and time-course of platelet inhibition following oral administration of P2Y12 …
-
Improving Medication Adherence Post-ST-Elevation Myocardial Infarction
… acid, second antiplatelet [clopidogrel, prasugrel, and ticagrelor], statin, beta-blocker, and angiotensin blocker). While in-hospital and discharge prescription rates for these essential life-saving medications is excellent, adherence is known to decline within weeks of hospital …
-
Investigating the Risk of Adverse Cardiovascular Events Associated with Concomitant Treatment of Clopidogrel and Protein Pump Inhibitors
… nonuse and adverse cardiovascular outcomes among prasugrel users or ticagrelor users (Chapter 5). Collectively, our findings do not provide evidence of an elevated risk of adverse cardiovascular outcomes with the combined use of PPIs and clopidogrel. Although pharmacodynamic and pharmacokinetic …
Page 1 of 2